|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,589.00 GBX | +0.39% |
|
-5.23% | +18.68% |
| Sep. 05 | Health Care Declines as Risk Aversion Weighs - Health Care Roundup | DJ |
| Sep. 05 | Sector Update: Health Care Stocks Fall Late Afternoon | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
| Capitalization | 256B | P/E ratio 2024 * |
29.5x | P/E ratio 2025 * | 25.2x |
|---|---|---|---|---|---|
| Enterprise value | 277B | EV / Sales 2024 * |
5.3x | EV / Sales 2025 * | 4.82x |
| Free-Float |
96.63% | Yield 2024 * |
1.86% | Yield 2025 * | 1.98% |
More valuation ratios
* Estimated data
More news
Last Transcript: AstraZeneca PLC
More press releases
More news
| 1 day | -3.88% | ||
| 1 week | -5.53% | ||
| Current month | -5.53% | ||
| 1 month | +0.66% | ||
| 3 months | +0.19% | ||
| 6 months | +24.01% | ||
| Current year | +18.30% |
1 week
12 540.00
13 388.00
1 month
12 412.0013 388.00
Current year
9 461.0013 388.00
1 year
9 461.0013 388.00
3 years
8 029.0013 388.00
5 years
5 871.0013 388.00
10 years
3 680.0013 388.00
| Director | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 99-03-31 | |
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 208 M€ | +13.88% | - | |
| 5.17% | 18 M€ | +7.76% | - | |
| 4.89% | 878 M€ | +9.13% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -3.88% | -5.53% | +16.80% | +47.37% | 256B | ||
| -3.55% | -2.92% | +63.52% | +251.69% | 822B | ||
| -2.16% | -4.01% | +33.76% | +181.19% | 583B | ||
| -1.42% | +0.46% | +2.68% | -5.74% | 397B | ||
| -2.11% | -1.19% | +32.01% | +72.78% | 341B | ||
| +2.41% | +0.96% | +10.31% | +53.49% | 301B | ||
| -1.07% | -3.22% | +8.78% | -24.28% | 262B | ||
| -1.99% | -2.95% | +12.67% | +18.64% | 236B | ||
| -1.90% | -2.01% | +27.70% | +43.29% | 174B | ||
| +0.42% | -0.73% | -19.42% | -39.13% | 162B | ||
| Average | -0.88% | -2.11% | +18.88% | +59.93% | 353.35B | |
| Weighted average by Cap. | -0.78% | -2.29% | +27.80% | +102.57% |
Financials
(USD)| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 52.21B | 56.12B |
| Net income | 8.66B | 10.25B |
| Net Debt | 20.82B | 14.76B |
More financial data
* Estimated data
Employees
89,900
Sector
Pharmaceuticals
Calendar
Related indices
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-09-06 | 12,570.00 p | +0.24% | 36,176 |
| 24-09-05 | 12,540.00 p | -3.88% | 2,305,262 |
| 24-09-04 | 13,046.00 p | -1.09% | 1,434,931 |
| 24-09-03 | 13,190.00 p | -0.65% | 909,842 |
| 24-09-02 | 13,276.00 p | +0.02% | 2,234,637 |
Delayed Quote London S.E., September 05, 2024 at 11:35 am EDT
More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
164.98USD
Average target price
183.81USD
Spread / Average Target
+11.42%
- Stock Market
- Equities
- AZN Stock
